Aspirin, PIK3CA mutation, and colorectal-cancer survival [4]

New England Journal of Medicine

Volumn 368, Issue 3, 2013, Pages 289-

  Sahin, Ibrahim H ^a   Garrett, Christopher ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 2; K RAS PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; CYCLOOXYGENASE 2 INHIBITOR; TUMOR MARKER;

CANCER SURVIVAL; COLORECTAL CANCER; DISEASE ASSOCIATION; DOWN REGULATION; ENZYME INHIBITION; ENZYME MECHANISM; GENE MUTATION; HUMAN; INHIBITION KINETICS; LETTER; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; COLORECTAL TUMOR; FEMALE; GENETICS; MALE; NOTE;

ASPIRIN; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2 INHIBITORS; FEMALE; HUMANS; MALE; PHOSPHATIDYLINOSITOL 3-KINASES; TUMOR MARKERS, BIOLOGICAL;

EID: 84872451258     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1214189     Document Type: Letter

References (3)

1. Rodriguez-Viciana P, Warne PH, Dhand R, et al. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 1994;370:527-32.
2. Smakman N, Kranenburg O, Vogten JM, Bloemendaal AL, van Diest P, Borel Rinkes IH. Cyclooxygenase-2 is a target of KRASD12, which facilitates the outgrowth of murine C26 colorectal liver metastases. Clin Cancer Res 2005;11:41-8.
3. Migliardi G, Sassi F, Torti D, et al. Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas. Clin Cancer Res 2012;18:2515-25.